This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Pedro Redondo, MD; Maria Luisa Subira, MD
Pamplona, Spain

Arch Intern Med. 1996;156(11):1238-1241.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The inhibition of the proinflammatory cytokine tumor necrosis factor a (TNF-) is considered an essential factor in the treatment of diseases as diverse as multiple sclerosis, rheumatoid arthritis, Crohn disease, systemic lupus erythematosus, and some forms of diabetes, as well as other diseases that involve selective immunologic attack on a particular organ or system.¹ In autoimmune disease, interleukin-1 (IL-1) acts by stimulating other cells to produce cytokines or enzymes that then act on the target tissue.² In addition, TNF- can stimulate the production of IL-1; hence, both molecules are likely to be involved in the pathogenesis of septic shock and other diseases. The cytokines IL-1β and TNF- are often grouped together and called proinflammatory cytokines. The biochemical changes induced by TNF- and IL-1β include increased synthesis of nitric oxide and endothelial cell adhesion molecules. Once TNF- and IL-1β are secreted, the cascade of inflammation erupts with secondary secretion . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?